Julie Mori

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations · Full text

Standard Deviations, Immunology, Pharmacotherapy +19

Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry

Mike Westby, Caroline Smith‐Burchnell, Julie Mori et al. · Journal of Virology · 2006 · 346 citations

Phenotypic Susceptibility Assays, Immunology, Ccr5 Antagonist +16

Structure and Mapping of the DNA of Human Parvovirus B19

Julie Mori, Paula Beattie, David W. Melton et al. · Journal of General Virology · 1987 · 93 citations

A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein

John P. DeVincenzo, Dereck Tait, John Efthimiou et al. · Antimicrobial Agents and Chemotherapy · 2019 · 84 citations · Full text

Dot blot hybridization assay of B19 virus DNA in clinical specimens

Julie Mori, A. M. Field, J P Clewley et al. · Journal of Clinical Microbiology · 1989 · 69 citations · Full text

Diagnostic Virology, Molecular Virology, Electron Microscopy +14